Tenderwize
Back to tender search

Non-exclusive drug discount agreement for Pegfilgrastim (ATC L03AA13) via open-house model

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Mar 31, 2028 · 540 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Pegfilgrastim (ATC-Code nach WHO: L03AA13)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

50 / 100

Complexity

30 / 100

Risk factors

No minimum volume or guaranteed revenue; actual demand depends on doctor prescribing and pharmacy dispensing behavior.

Potential early termination if exclusive agreements are concluded; the notice states this typically occurs 8–12 months...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Mar 31, 2028

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Non-exclusive discount agreements for Pegfilgrastim (ATC L03AA13) under § 130a Abs. 8 SGB V.
  • Open-house model: continuous participation, no negotiations, no exclusivity.
Show full summary

Non-exclusive drug discount agreement for Pegfilgrastim (ATC L03AA13) via an open-house model by AOK PLUS, covering Saxony and Thuringia, Germany. No guaranteed volume; continuous participation; contract until 31 March 2028. Procurement law formally applies due to publication form, but the procedure is not a classic public procurement.

Risks

No minimum volume or guaranteed revenue; actual demand depends on doctor prescribing and pharmacy dispensing behavior.

Potential early termination if exclusive agreements are concluded; the notice states this typically occurs 8–12 months...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in § 4 Abs. 18 AMG.

Eligibility

  • Must not be subject to mandatory or discretionary exclusion grounds under §§ 123, 124 GWB.
  • Must provide self-declarations: exclusion grounds and Russia sanctions (EU Regulation 833/2014).

Requirements may be incomplete.

Award Criteria

Lot 1

Not specified; award criteria field is a technicality and not binding per the notice.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive drug discount agreement for Pegfilgrastim (ATC L03AA13) via open-house model

Conclusion of non-exclusive discount agreements for the active ingredient Pegfilgrastim. Open to all qualified pharmaceutical entrepreneurs. No volume guarantees. Contract ends 31 March 2028 regardless of signing date. Subject to early termination if exclusive agreements are concluded.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Apr 2026 - Mar 2028

Category

Pharmaceutical products

Award Criteria

Not specified; award criteria field is a technicality and not binding per the notice.

Deadline

Deadline Mar 31, 2028

Procurement Details

Publication date
19 Feb 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
122544-2026

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30